Search results
Author(s):
Alexander G Truesdell
,
Jaime A Hernandez-Montfort
,
Varinder Kaur Randhawa
Added:
2 years ago
In this in-depth discussion lead by Dr Alexander Truesdell (Virginia Heart/Inova Heart & Vascular Institute, US), contributors of Cardiogenic Shock Special Focus Collection, Dr Varinder K Randhawa (Cleveland Clinic, US) and Dr Jaime Hernandez-Montfort (Cleveland Clinic Florida, US) discuss the most prevalent questions on hemodynamic-based assessment and management of cardiogenic shock:
What is…
View more
Author(s):
Ricardo Seabra-Gomes
,
Jorge Ferreira
Added:
3 years ago
Cardiogenic shock (CS) is a state of systemic tissue hypoperfusion due to cardiac failure in the presence of adequate intravascular volume.1 Left ventricular pump failure leading to CS remains one of the most serious and challenging conditions over time in cardiology and is still the most common cause of hospital mortality associated with myocardial infarction (MI).2 This review focuses on CS in…
View more
Author(s):
Abhijeet Dhoble
Added:
10 months ago
EuroPCR 23 —We are joined by Dr Abhijeet Dhoble (UT Health, US) to discuss the findings of the TVT-registry analysis on transcatheter aortic valve replacement (TAVR) in patients with cardiogenic shock. (NCT01737528)
The analysis aims to evaluate the outcomes of balloon-expandable bioprosthetic transcatheter aortic valve replacement (TAVR) with SAPIEN 3 and SAPIEN 3 Ultra bioprosthesis in…
View more
Author(s):
Lee Chang
,
Robert Yeh
Added:
3 years ago
Cardiogenic shock is the leading cause of death in patients with acute ST-elevation myocardial infarction (STEMI). Characterised by a state of low cardiac output leading to end-organ hypoperfusion, cardiogenic shock complicates approximately 5–8 % of STEMIs and is associated with a mortality rate approaching 50 percent.1–3 Prompt recognition and therapeutic intervention for cardiogenic shock due…
View more
Author(s):
Petr Ostadal
,
Saahil A Jumkhawala
Added:
1 year ago
AHA 22 - CardioNerds Fellow, Dr Saahil A Jumkhawala (Rutgers New Jersey Medical School, US) is joined by investigator, Dr Petr Ostadal (Na Homolce Hospital, CZ) to talk about the ECMO-CS trial (NCT02301819).
In the ECMO-CS trial 122 patients with rapidly deteriorating or severe cardiogenic shock were randomized to receive veno-arterial extracorporeal membrane oxygenation (ECMO) or early…
View more
Author(s):
Uwe Zeymer
Added:
4 months ago
AHA 23 - We are joined on-site by Prof Uwe Zeymer (Klinikum Ludwigshafen, Ludwigshafen, DE) to discuss the findings from a sub-analysis of the ECLS-SHOCK trial.This sub-analysis investigates the impact of cardiac arrest before randomisation on the efficacy of ECLS in patients with infarct-related cardiogenic shock. Investigators enrolled 420 patients with acute MI and cardiogenic shock across 41…
View more
Author(s):
Harriette Van Spall
,
Holger Thiele
Added:
7 months ago
ESC 2023 – Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Prof Holger Thiele (Heart Center Leipzig at University of Leipzig, DE) to discuss the findings from the ECLS-SHOCK trial (NCT03637205).
The leading cause of death in hospitalised patients with acute myocardial infarction is cardiogenic shock. Efforts to improve outcomes for these patients has led to…
View more
Alexander G Truesdell
Author
Author(s):
José PS Henriques
Added:
3 years ago
Despite considerable improvements in the treatment of acute ST elevation myocardial infarction (STEMI), outcomes have predominantly improved in STEMI patients without cardiogenic shock (CS). Nevertheless, cardiogenic shock occurs in approximately 7–10% of STEMI patients and is the leading cause of death for hospitalised patients. In-hospital mortality rates of STEMI complicated by CS are around…
View more
Srikant Patlolla
Research Area(s) / Expertise:
Job title: Advanced Heart Failure and Transplant Cardiology Fellow
Author